Gilteritinib – XOSPATA (USA)

According to the NCI website, Gilteritinib is an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-related tyrosine kinase 3, AXL and anaplastic lymphoma kinase, with potential antineoplastic activity. Check for active clinical trials using this agent.

Indikationen/Anwendungsmöglichkeiten gemäss Compendium.ch^®

• Behandlung von erwachsenen Patienten, die an rezidivierter oder refraktärer akuter myeloider Leukämie (AML) mit FMS-ähnlichen Tyrosinkinase 3 (FLT3)-Mutationen leiden (siehe «Klinische Wirksamkeit»).

More Information in English:

Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health

Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute

Wiki

Link zu PharmaWiki
Link to Physicians Desk Reference (PDR)
Link to European Medicines Agency (EMEA)
Info for Patients presented by Scott Hamilton from Chemocare.com

receptor tyrosine kinase